In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as IL-12/23 inhibitor Stelara (Janssen), have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—Celgene’s Otezla (2014), Novartis’s Cosentyx (2015), Eli Lilly’s Taltz (2016), Valeant’s Siliq (2017), Janssen’s Tremfya (2017), and Sun Pharma’s Ilumya (2018)—is anticipated to substantially alter the market landscape. The Psoriasis Emerging Therapies series includes three waves that will track the awareness, trial, and use of Tremfya after its launch in July 2017 for the treatment of psoriasis. In addition, the series will examine physicians’ anticipation of future trends in psoriasis treatment, particularly Tremfya’s uptake, and assess Janssen’s promotional efforts.
Questions Answered:
What is the awareness of, familiarity with, and perceptions related to Tremfya among U.S. dermatologists?
According to prescribers, to which patients are they prescribing Tremfya, why are they prescribing Tremfya, and how satisfied are they with Tremfya ?
How do prescribers and nonprescribers compare across key metrics?
How is the trial and adoption of Tremfya tracking compared to other recent product launches in the autoimmune market?
Product Description:
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Benchmarking Tremfya's Launch Success vs. Other Launched Drugs
Prescriber and Nonprescriber Profiles
Differences Between Tremfya Prescribers and Nonprescribers
Differences Between Tremfya Prescriber and Nonprescriber Profiles
Tremfya Awareness and Perceptions
Unaided and Aided Awareness of Tremfya
Unaided Awareness of Approved Drugs for Psoriasis
Recent Changes Made to Psoriasis Treatment
Awareness of Tremfya
Awareness of Tremfya's Approval for Psoriasis
Awareness of Tremfya's Dosing
Estimated Cost of Tremfya
Familiarity with Tremfya
Sources of Familiarity with Tremfya
Initial Reaction to and Interest in Tremfya
Tremfya Product Profile
Initial Reaction to Tremfya After Viewing Product Profile
Initial Reaction to Tremfya After Viewing Product Profile: Mean
Initial Reaction to Key Attributes of Tremfya After Viewing Product Profile
Initial Reaction to Key Attributes of Tremfya After Viewing Product Profile: Mean
Interest in Learning More About Tremfya
Interest in Learning More About Tremfya: Mean
Impressions of Tremfya
Tremfya Attributes of Which Dermatologists Were Unaware
Aspects of Tremfya Profile of Which Dermatologists Were Unaware
Perceived Uniqueness of Tremfya
Perceived Uniqueness of Tremfya: Mean
Risk-Benefit Ratio of Tremfya
Risk-Benefit Ratio of Tremfya: Mean
Unaided Advantages of Tremfya
Unaided Disadvantages of Tremfya
Prescriber and Nonprescriber Profiles
Differences Between Tremfya Prescriber and Nonprescriber Profiles
Tremfya Trial and Use
Willingness to Prescribe Tremfya
Willingness to Prescribe Tremfya to Psoriasis Patients
Willingness to Prescribe Tremfya to Psoriasis Patients: Mean
Impact of Attributes on Willingness to Prescribe Tremfya
Impact of Attributes on Willingness to Prescribe Tremfya: Mean
Number of Patients Currently Receiving Tremfya
Tremfya Patient Volume
Timing of Tremfya Prescription
Tremfya Discontinuation Rate
Agents to Which Patients Switched After Discontinuing Tremfya
Biologics and Novel Oral Agents Currently Prescribed to Psoriasis Patients
Disease Severity of Tremfya-Treated Patients
Origination of Patients Treated with Tremfya
Agents from Which Patients Were Switched to Tremfya
Therapies to Which Tremfya Was Added
Reasons for Prescribing Tremfya
Number of Patient Inquiries for Tremfya
Number of Patient Inquiries for Tremfya: Mean Number of Patients
Result of Specific Patient Requests for Tremfya
Reasons for Not Yet Prescribing Tremfya
Anticipated Tremfya Use
Nonprescriber Timeline for Tremfya Trial
Anticipated New Tremfya Users in the Next Month
Candidates for Tremfya by Psoriasis Patient Population
Candidates for Tremfya by Treatment History
Therapies That Tremfya Is Likely to Replace
Obstacles to Prescribing Tremfya
Anticipated Prescribing of Biologics and Novel Oral Agents for Psoriasis in the Next Six Months
Tremfya Performance on Key Attributes
Overall Satisfaction with Tremfya
Reasons for High Overall Satisfaction with Tremfya
Ease of Tremfya's Managed Care Approval Process
Requirements for Tremfya's Managed Care Approval
Mean Total Tremfya Performance on Key Attributes
Mean Tremfya Performance on Key Attributes: Prescribers vs. Nonprescribers
Tremfya Performance on Key Attributes: Prescribers vs. Nonprescribers
Total Tremfya Performance on Key Attributes
Effectiveness of Face-to-Face Detailing for Tremfya
Tremfya Sales Representative Frequency and Reach
Most Recent Contact with a Tremfya Representative
Frequency of Tremfya Representative Visits to Surveyed Dermatologists
Frequency of Tremfya Representative Visits to Surveyed Dermatologists: Mean
Satisfaction with Tremfya Sales Representative
Performance of Tremfya Sales Representatives
Performance of Tremfya Sales Representatives: Mean
Tremfya Message Recall
Message Recall During Recent Detail
Percentage of Physicians Who Received Ideal Tremfya Candidate Suggestion from Representative
Ideal Tremfya Candidate Suggestions Made by Representative
Materials Used During Tremfya Sales Representative Visit
Agents Positioned Against Tremfya During Representative Visit
Appendix
Additional Primary Market Research
Anticipated New Tremfya Users in the Next Month: Mean Number of Patients
Patients Treated by Disease Severity
Percentage of Patients Receiving Prescription Drug Therapy
Percentage of Patients Receiving Prescription Drug Therapy by Treatment Category
Percentage of Patients Receiving Phototherapy
Timing of Tremfya Prescription: Mean Number of Patients
Tremfya Discontinuation Rate: Mean Number of Patients
Disease Severity of Tremfya-Treated Patients: Mean Number of Patients
Reasons for Discontinuing Tremfya
Average Time Between Tremfya Initiation and Discontinuation
Average Time Between Tremfya Initiation and Discontinuation: Mean Number of Patients
Abbreviations
Mohit Nasa, M.B.A.
Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Previously, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.